Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wang, Qingwei, Guo, Liangsheng, Wang, Shuai, Guan, Chengdan, Pan, Junhao, Zhu, Shaoping, Zheng, Lei, Wu, Xuehua, Gu, Yonghui, Shu, Tao, Luo, Lianxiang, Lai, Tianwen, Gao, Xiao
Format: Artículo científico
Sprache:en
Veröffentlicht: BMC biology 2026
Schlagworte:
Online-Zugang:https://pubmed.ncbi.nlm.nih.gov/41546036/
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1868266097718853632
author Wang, Qingwei
Guo, Liangsheng
Wang, Shuai
Guan, Chengdan
Pan, Junhao
Zhu, Shaoping
Zheng, Lei
Wu, Xuehua
Gu, Yonghui
Shu, Tao
Luo, Lianxiang
Lai, Tianwen
Gao, Xiao
author_facet Wang, Qingwei
Guo, Liangsheng
Wang, Shuai
Guan, Chengdan
Pan, Junhao
Zhu, Shaoping
Zheng, Lei
Wu, Xuehua
Gu, Yonghui
Shu, Tao
Luo, Lianxiang
Lai, Tianwen
Gao, Xiao
Wang, Qingwei
Guo, Liangsheng
Wang, Shuai
Guan, Chengdan
Pan, Junhao
Zhu, Shaoping
Zheng, Lei
Wu, Xuehua
Gu, Yonghui
Shu, Tao
Luo, Lianxiang
Lai, Tianwen
Gao, Xiao
collection PubMed - marine biology
contents BRD4-mediated transcriptional activation of PDLIM4 enhances p21 stability and chemosensitivity in lung adenocarcinoma independent of p53. Wang, Qingwei Guo, Liangsheng Wang, Shuai Guan, Chengdan Pan, Junhao Zhu, Shaoping Zheng, Lei Wu, Xuehua Gu, Yonghui Shu, Tao Luo, Lianxiang Lai, Tianwen Gao, Xiao Humans Bromodomain Containing Proteins Adenocarcinoma of Lung Transcription Factors Lung Neoplasms LIM Domain Proteins Cell Cycle Proteins Cyclin-Dependent Kinase Inhibitor p21 Tumor Suppressor Protein p53 Animals Transcriptional Activation Cell Line, Tumor Mice Gene Expression Regulation, Neoplastic Understanding p53-independent regulatory mechanisms is crucial for predicting outcomes in lung adenocarcinoma (LUAD) and developing improved therapeutic strategies. We found that PDLIM4 is highly expressed in LUAD tumor tissues, where it induces G2/M phase cell cycle arrest and suppresses cell proliferation, suggesting its potential role in improving patient prognosis. Our study identified BRD4, a bromodomain and extraterminal (BET) family protein, as a key transcriptional regulator of PDLIM4, acting through its BD1 domain. Further analysis revealed that wild-type PDLIM4 stabilizes p21 by blocking its RNA degradation, leading to p21 protein accumulation and subsequent inhibition of cell proliferation. In contrast, the S116 mutation in PDLIM4 abrogates this regulatory effect. Notably, activation of the BRD4/PDLIM4/p21 pathway enhanced chemosensitivity to doxorubicin in both LUAD cells and xenograft tumor models. Given the high mutation frequency of PDLIM4 recorded in the TCGA cancer database, our findings reveal a critical regulatory signaling pathway that suppresses LUAD progression and augments chemotherapy efficacy.
format Artículo científico
id pubmed_41546036
institution PubMed
language en
publishDate 2026
publisher BMC biology
record_format pubmed
spellingShingle BRD4-mediated transcriptional activation of PDLIM4 enhances p21 stability and chemosensitivity in lung adenocarcinoma independent of p53.
Wang, Qingwei
Guo, Liangsheng
Wang, Shuai
Guan, Chengdan
Pan, Junhao
Zhu, Shaoping
Zheng, Lei
Wu, Xuehua
Gu, Yonghui
Shu, Tao
Luo, Lianxiang
Lai, Tianwen
Gao, Xiao
Humans
Bromodomain Containing Proteins
Adenocarcinoma of Lung
Transcription Factors
Lung Neoplasms
LIM Domain Proteins
Cell Cycle Proteins
Cyclin-Dependent Kinase Inhibitor p21
Tumor Suppressor Protein p53
Animals
Transcriptional Activation
Cell Line, Tumor
Mice
Gene Expression Regulation, Neoplastic
BRD4-mediated transcriptional activation of PDLIM4 enhances p21 stability and chemosensitivity in lung adenocarcinoma independent of p53. Wang, Qingwei Guo, Liangsheng Wang, Shuai Guan, Chengdan Pan, Junhao Zhu, Shaoping Zheng, Lei Wu, Xuehua Gu, Yonghui Shu, Tao Luo, Lianxiang Lai, Tianwen Gao, Xiao Humans Bromodomain Containing Proteins Adenocarcinoma of Lung Transcription Factors Lung Neoplasms LIM Domain Proteins Cell Cycle Proteins Cyclin-Dependent Kinase Inhibitor p21 Tumor Suppressor Protein p53 Animals Transcriptional Activation Cell Line, Tumor Mice Gene Expression Regulation, Neoplastic Understanding p53-independent regulatory mechanisms is crucial for predicting outcomes in lung adenocarcinoma (LUAD) and developing improved therapeutic strategies. We found that PDLIM4 is highly expressed in LUAD tumor tissues, where it induces G2/M phase cell cycle arrest and suppresses cell proliferation, suggesting its potential role in improving patient prognosis. Our study identified BRD4, a bromodomain and extraterminal (BET) family protein, as a key transcriptional regulator of PDLIM4, acting through its BD1 domain. Further analysis revealed that wild-type PDLIM4 stabilizes p21 by blocking its RNA degradation, leading to p21 protein accumulation and subsequent inhibition of cell proliferation. In contrast, the S116 mutation in PDLIM4 abrogates this regulatory effect. Notably, activation of the BRD4/PDLIM4/p21 pathway enhanced chemosensitivity to doxorubicin in both LUAD cells and xenograft tumor models. Given the high mutation frequency of PDLIM4 recorded in the TCGA cancer database, our findings reveal a critical regulatory signaling pathway that suppresses LUAD progression and augments chemotherapy efficacy.
title BRD4-mediated transcriptional activation of PDLIM4 enhances p21 stability and chemosensitivity in lung adenocarcinoma independent of p53.
topic Humans
Bromodomain Containing Proteins
Adenocarcinoma of Lung
Transcription Factors
Lung Neoplasms
LIM Domain Proteins
Cell Cycle Proteins
Cyclin-Dependent Kinase Inhibitor p21
Tumor Suppressor Protein p53
Animals
Transcriptional Activation
Cell Line, Tumor
Mice
Gene Expression Regulation, Neoplastic
url https://pubmed.ncbi.nlm.nih.gov/41546036/